tiprankstipranks
pc:vaxim

Vaximm AG

Vaximm AG is a privately held Swiss-German biotechnology company focused on developing orally administered T-cell vaccination therapies using live, attenuated bacterial vectors to deliver tumor-associated antigens. The company’s lead candidate, VXM01, targets VEGFR-2 and has demonstrated clinical activity and safety across multiple cancer indications.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$30M
Total Amount Raised$30M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$30M
Latest Funding Amount$30M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jan 12, 2026
Investment
$30.00M

Investors

Investor Name
Funding Round

Related News and Analysis